Haemonetics launches VASCADE MVP XL mid-bore venous closure device with FDA pre-market approval.

From Nasdaq: 2024-06-19 13:26:00

Haemonetics Corporation (HAE), a global medical technology company, has launched the VASCADE MVP XL mid-bore venous closure device with innovative technology for rapid hemostasis, expanding their vascular closure solutions.

The VASCADE MVP XL system is designed for mid-bore venous closure with larger discs and more collagen compared to the previous system, receiving pre-market approval from the FDA.

The global vascular closure devices market is projected to grow to $3.30 billion by 2033, driven by increasing cardiovascular procedures, making Haemonetics’ timing for expanding their VASCADE portfolio ideal.

Haemonetics also recently received FDA clearance for the TEG 6s system and acquired Attune Medical to enhance their revenue, showing a positive outlook for the company’s growth.

HAE shares have outperformed the industry in the past year, with a Zacks Rank #1 (Strong Buy) and other top medical stocks like Hims & Hers Health and Lantheus Holdings showing promising performance.



Read more at Nasdaq: Haemonetics (HAE) Expands VASCADE Line With New Limited Launch